EICHORPublic-registry trials using SHR0302 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
SHR0302 appears in 1 registered trial Eichor's radar has found, sponsored by Reistone Biopharma Company Limited, the most recent registered as Phase 2, with a planned enrollment of 112. Registered timeline: 2019–2021. The registry holds 2,063 registered studies for Crohn's Disease.
| Trial | Sponsor | Condition | Phase | Sites |
| A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease | Reistone Biopharma Company Limited | Crohn's Disease | PHASE2 | 82 |
| Status | Completed · planned start 2019-05 |
| Primary completion | 2021-09 |
| Enrollment target | 112 participants |
| Design | Randomized · Parallel · Phase 2 · 4 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 82 listed in China, Poland, Ukraine, United States |
All fields verbatim from the ClinicalTrials.gov record for NCT03677648.
| First registered study | April 2015 — NCT02423538 (Jiangsu HengRui Medicine Co., Ltd.) |
| Registered studies matching this name | 32 all-time · 3 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 2,063 registered studies for Crohn's Disease. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Crohn's Disease studies · Weekly briefs
